Objective To compare levofloxacin and ofloxacin in the treatment of multidrug-resistant
tuberculosis (MDR-TB). Patients and methods A retrospective analysis of 106 patients with …

Background There is a need for short and safe all-oral treatment of rifampicin-resistant
tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients …

Background Recent World Health Organization guidance on drug-resistant tuberculosis
treatment de-prioritised injectable agents, in use for decades, and endorsed all-oral longer …

Background With the introduction of new anti-tuberculosis drugs, all-oral regimens with
shorter treatment durations for multidrug-resistant tuberculosis have been anticipated. We …

This study compared the efficacy of moxifloxacin and levofloxacin in the treatment of
multidrug-resistant tuberculosis (MDR-TB) in Shanghai, China. A retrospective analysis of …

Background Multidrug-resistant tuberculosis (MDR-TB) patients have been suffering long,
ineffective, and toxic treatment until short-course injectable-free regimens emerged …

ABSTRACT Objectives World Health Organization recommends a 7-drug 9–11-month
rifampicin-resistant tuberculosis (RR-TB) short treatment regimen (STR). To reduce the pill …

Treatment of drug-resistant tuberculosis is lengthy, insufficiently effective, and toxic. Since
2016, the World Health Organization has recommended shorter treatment regimens (STR) …

Background Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) remain
unsatisfactory, and long-term use of second-line anti-TB drugs is accompanied by the …

Background Early-phase and preclinical studies suggest that moxifloxacin-containing
regimens could allow for effective 4-month treatment of uncomplicated, smear-positive …